Given the growing knowledge of the distinct clinical course and prognosis associated with tumor subtypes, we sought to characterize BOM patients by tumor subtype (TS) using hormonal receptor (HR) and HER2 status. This evidence concerns the gene ERBB2 and neoplasm.